Clinical Study of Sulfotanshinone Sodium Injection in Treating Non-Ischemic Retinal Vein Occlusion

Bingwen Lu, Xingwei Wu^*

Ophthalmology Department, Shanghai First People’s Hospital, Shanghai, China.

DOI: 10.4236/cm.2015.62009                

Abstract

Objectives: To study the effect of sulfotanshinone sodium (SS) injection in the treatment of non-ischemic retinal vein occlusion (RVO). Methods: Sixty-two RVO patients treated in our hospital between Jan. 2013 and Oct. 2014 were randomly divided into Control Group (30 patients; Bendazol tablets) and Treatment Group (32 patients, Bendazol tablets + SS injections), each with a follow-up period of 6 months. Statistical analysis was then performed on changes in visual acuity, central retinal thickness (CRT) and retinal circulation time (RCT) before and after the treatment. Results: After treatment, both Control Group and Treatment Group witnessed an improvement on visual acuity (Control Group: t = 2.103, p = 0.044; Treatment Group: t = 8.021, p = 0.000). Visual acuity could be greatly improved in Treatment Group when compared with Control Group, with significant differences (p < 0.01). Macular edema could be greatly relieved in Treatment Group measured by CRT (t = 2.571, p = 0.007) while the difference was of no statistical significance in Control Group (t = 1.016, p = 0.070). RCT were remarkably shortened in both groups (Control Group: t = 43.83, p = 0.000; Treatment Group: t = 27.34, p = 0.000), and when compared with Control group, the changes in Treatment Group were more significant (p < 0.05). Conclusion: SS injection could effectively improve the therapeutic effect in patients with non-ischemic retinal vein occlusion.

Keywords

Sulfotanshinone Sodium Injection, Non-Ischemic Retinal Vein Occlusion

Conflicts of Interest

The authors declare no conflicts of interest.

References

[1]	Querques, G., Triolo, G., Casalino, G., García-Arumí, J., Badal, J., Zapata, M., Boixadera, A., Castillo, V.M. and Bandello, F. (2013) Retinal Venous Occlusions: Diagnosis and Choice of Treatments. Ophthalmic Research, 49, 215-222. http://dx.doi.org/10.1159/000346734
[2]	Hahn, P. and Fekrat, S. (2012) Best Practices for Treatment of Retinal Vein Occlusion. Current Opinion in Ophthalmology, 23, 175-181. http://dx.doi.org/10.1097/ICU.0b013e3283524148
[3]	Cernak, M. and Struharova, K. (2012) Current Therapy for Retinal Vein Occlusion. Bratisl Lek Listy, 113, 228-231. http://dx.doi.org/10.4149/BLL_2012_052
[4]	Zhou, L., Zuo, Z. and Chow, M.S. (2005) Danshen: An Overview of Its Chemistry, Pharmacology, Pharmacokinetics, and Clinical Use. The Journal of Clinical Pharmacology, 45, 1345-1359. http://dx.doi.org/10.1177/0091270005282630
[5]	Chen, Y., Wu, X., Yu, S., Lin, X., Wu, J., Li, L., Zhao, J. and Zhao, Y. (2012 Neuroprotection of Tanshinone IIA against Cerebral Ischemia/Reperfusion Injury through Inhibition of Macrophage Migration Inhibitory Factor in Rats. PLoS ONE, 7, e40165. http://dx.doi.org/10.1371/journal.pone.0040165
[6]	Fu, J., Huang, H., Liu, J., Pi, R., Chen, J. and Liu, P. (2007) Tanshinone IIA Protects Cardiac Myocytes against Oxidative Stress-Triggered Damage and Apoptosis. European Journal of Pharmacology, 568, 213-221. http://dx.doi.org/10.1016/j.ejphar.2007.04.031
[7]	Park, O.K., Choi, J.H., Park, J.H., Kim, I.H., Yan, B.C., Ahn, J.H., Kwon, S.H., Lee, J.C., Kim, Y.S., Kim, M., Kang, I.J., Kim, J.D., Lee, Y.L. and Won, M.H. (2012) Comparison of Neuroprotective Effects of Five Major Lipophilic Diterpenoids from Danshen Extract against Experimentally Induced Transient Cerebral Ischemic Damage. Fitoterapia, 83, 1666-1674. http://dx.doi.org/10.1016/j.fitote.2012.09.020
[8]	Shang, Q.H., Xu, H. and Huang, L. (2012) Tanshinone IIA: A Promising Natural Cardioprotective Agent. Evidence-Based Complementary and Alternative Medicine, 2012, Article ID: 716459. http://dx.doi.org/10.1155/2012/716459
[9]	Chen, Y.L., Wu, X.M., Yu, S.S., Lin, X.M., Wu, J.X., Li, L., Zhao, J. and Zhao, Y. (2012) Neuroprotection of Tanshinone IIA against Cerebral Ischemia/Reperfusion Injury through Inhibition of Macrophage Migration Inhibitory Factor in Rats. PLoS ONE, 7, e40165. http://dx.doi.org/10.1371/journal.pone.0040165
[10]	Li, X.X., Xu, X., Wang, J.N., Yu, H., Wang, X., Yang, H.J., Xu, H.Y., Tang, S.H., Li, Y., Yang, L., Huang, L.Q., Wang, Y.H. and Yang, S.L. (2012) A System-Level Investigation into the Mechanisms of Chinese Traditional Medicine: Compound Danshen Formula for Cardiovascular Disease Treatment. PLoS ONE, 7, e43918. http://dx.doi.org/10.1371/journal.pone.0043918
[11]	Wang, A.-M., Sha, S.-H., Lesniak, W. and Schacht, J. (2003) Tanshinone (Salviae miltiorrhizae Extract) Preparations Attenuate Aminoglycoside-Induced Free Radical Formation in Vitro and Ototoxicity in Vivo. Antimicrobial Agents and Chemotherapy, 47, 1836-1841. http://dx.doi.org/10.1128/AAC.47.6.1836-1841.2003
[12]	Zhang, M.-Q., Zheng, Y.-L., Chen, H., Tu, J.-F., Shen, Y., Guo, J.-P., Yang, X.-H., Yuan, S.-R., Chen, L.-Z., Chai, J.-J., Lu, J.-H. and Zhai, C.-L. (2013) Sodium Tanshinone IIA Sulfonate Protects Rat Myocardium against Ischemia-Reperfusion Injury via Activation of PI3K/Akt/FOXO3A/Bim Pathway. Acta Pharmacologia Sinica, 34, 1386-1396. http://dx.doi.org/10.1038/aps.2013.91
[13]	Tan, X.Y., Li, J.P., Wang, X.Y., Chen, N., Cai, B.Z., Wang, G., Shan, H.L., Dong, D.L., Liu, Y.J., Li, X.D., Yang, F., Li, X., Zhang, P., Li, X.Q. Yang, B.F. and Lu, Y.J. (2011) Tanshinone IIA Protects against Cardiac Hypertrophy via Inhibiting Calcineurin/Nfatc3 Pathway. International Journal of Biological Sciences, 7, 383-389. http://dx.doi.org/10.7150/ijbs.7.383
[14]	Xu, S. and Liu, P. (2013) Tanshinone II-A: New Perspectives for Old Remedies. Expert Opinion on Therapeutic Patents, 23, 149-153. http://dx.doi.org/10.1517/13543776.2013.743995